Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Patents (Class 514/283)
  • Publication number: 20150118322
    Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 30, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Ya-Chin LO, Hsiang-Fa LIANG, Ming-Cheng WEI, Maggie J.M. LU, Min-Ying LIN, Chih-Peng LIU, Chun-MIN LIU, Hsiang-Wen TSENG, Tse-Min TENG, Jui-Hsiang CHEN, Yi-Man CHOU, Yi-Ting HSIEH, Chia-Mu TU
  • Publication number: 20150119388
    Abstract: An ester of ArOH according to the formula R—X—CO—OAr, wherein ArOH is a pharmaceutically active compound selected from the group consisting of SN-38, PI-103, etoposide and fenretinide, wherein a) R is a residue of cholesterol, sitosterol, SN-38, PI-103, etoposide or fenretinide and X is O—CO-L, wherein L is either a direct bond or a linking group including a branched or unbranched hydrocarbyl moiety that may optionally include in-chain or pendant heteroatom substituents and/or cyclic moieties; b) R—X—CO-0 is an all-trans retinoate radical or the 9-cis or 13-cis isomer thereof; or c) R—X— is a branched or unbranched, saturated or unsaturated hydrocarbyl moiety comprising at least 5 carbon atoms and optionally including at least one in-chain or pendant heteroatom substituent and/or cyclic moiety.
    Type: Application
    Filed: June 14, 2013
    Publication date: April 30, 2015
    Applicant: THE CHILDREN'S HOSPITAL PHILADELPHIA
    Inventors: Ivan Alferiev, Michael Chorny, Garrett M. Brodeur, Robert J. Levy
  • Publication number: 20150111918
    Abstract: Methods for treating a patient using therapeutic immune system neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including modulating nerves proximate a vessel or duct of an immune system organ using an intravascularly or intraluminally positioned therapeutic element. One or more measurable physiological parameters corresponding to an immune system disorder, a condition associated with sympathetic activity in an immune system organ, or a condition associated with central sympathetic activity in the patient can thereby be reduced.
    Type: Application
    Filed: March 7, 2013
    Publication date: April 23, 2015
    Inventors: Paul Sobotka, Neil Barman
  • Patent number: 9006439
    Abstract: Disclosed are novel camptothecin derivatives having anti-tumor activity (the basic structure thereof is as shown in the figure) and compositions of such compounds and use thereof. The compounds according to the present invention exhibit very good water solubility and stability, show good selectivity among drugs of the same category, and have a very high therapeutic index. Such compounds are promising as therapeutic agents for treating tumors.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: April 14, 2015
    Assignee: Ningbo Team Pharmaceutical Co., Ltd
    Inventors: Xiaoguang Lei, Xiuguo Zhang
  • Publication number: 20150093328
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Application
    Filed: April 17, 2013
    Publication date: April 2, 2015
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendricks, Samuel Agresta, Helen Lee
  • Publication number: 20150094276
    Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
    Type: Application
    Filed: April 19, 2013
    Publication date: April 2, 2015
    Inventor: Roger D. Tung
  • Publication number: 20150087668
    Abstract: Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 26, 2015
    Applicant: Nektar Therapeutics
    Inventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
  • Publication number: 20150087633
    Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Donald D. Payan, Sylvia Braselmann
  • Patent number: 8987292
    Abstract: The present invention relates to compositions and methods for treating rectal disorders.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: March 24, 2015
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Alan Safdi, David Taylor
  • Publication number: 20150079189
    Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.
    Type: Application
    Filed: September 13, 2014
    Publication date: March 19, 2015
    Applicant: Arbor Therapeutics, LLC
    Inventors: James D. McChesney, Igor Nikoulin, Steve J. Bannister, Douglas L. Rodenburg
  • Publication number: 20150080353
    Abstract: The subject invention relates to compositions and methods useful for the in vivo delivery of substantially water-insoluble drugs, like taxol. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 19, 2015
    Inventors: Mewa SINGH, Maninder SANDHU
  • Patent number: 8980909
    Abstract: The disclosure includes hydroxamic compounds of Formula I: (Formula I) wherein Z, L, R1, R2, and R3 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: March 17, 2015
    Assignee: Crystal Biopharmaceutical LLC
    Inventors: Yi Chen, Yu Chen
  • Publication number: 20150073003
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Arie DAGAN, Shimon SLAVIN, Shimon GATT, Jeremy ZAHAVY
  • Publication number: 20150072949
    Abstract: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice for treating pancreatic cancer.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Ilan ZIV, Hagit GRIMBERG
  • Publication number: 20150073008
    Abstract: The present invention provides pharmaceutical compositions comprising a vinca alkaloid of formula (I): or a pharmaceutically acceptable salt (or hydrate) thereof, wherein each of R1, R2, R3, and R4 is as defined and described herein, wherein said formulations are useful for the topical treatment of actinic keratosis.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 12, 2015
    Inventors: Bhushan Hardas, Harry Frank Abts, Thomas Hengl, Kim Schlinzig, Alan Fleischer, Sarah Caley, Jon Parrish, Lutz Franke
  • Publication number: 20150072008
    Abstract: The invention defines a nonwoven membrane for the controlled and sustained release of a therapeutic or cosmetic active agent in the area of the body to be treated. This nonwoven membrane comprises one single type of biocompatible electrospun nanofibers and microparticles of at least one therapeutic or cosmetic active agent which are entangled between the nanofibers, the active agent having a low water solubility.
    Type: Application
    Filed: March 27, 2013
    Publication date: March 12, 2015
    Inventors: Jose Antonio Tornero Garcia, Angel Montero Carcaboso, Joan Bertran I Llavina
  • Publication number: 20150065945
    Abstract: Methods for treating a patient using therapeutic spinal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including modulating nerves of one or more targeted organs proximate one or more dorsal root ganglia, stellate ganglia, vertebral ganglia, or cervical ganglia of the nerves using an intravascularly-positioned therapeutic element. One or more measurable physiological parameters corresponding to at least one condition associated with sympathetic activity in the targeted organs and/or central sympathetic activity in the patient can thereby be reduced.
    Type: Application
    Filed: March 7, 2013
    Publication date: March 5, 2015
    Inventors: Denise Zarins, Sean Ward
  • Publication number: 20150064175
    Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 5, 2015
    Inventors: Gilles H. Tapolsky, Pooran Chand
  • Publication number: 20150057305
    Abstract: Disclosed in the present invention is a pharmaceutical composition, comprising a weight ratio of 1:120 to 1:1000 of camptothecin compound of formula I and ?-cyclodextrin or derivatives thereof, and an acidic buffer to adjust the pH=3.5-6.0. The composition can be used to treat solid tumours, such as melanoma, pancreatic cancer, hepatoma etc. The pharmaceutical composition of the present invention is miscible with a water-miscible co-solvent system in any proportion, and can be used as an intravenous infusion solvent, and has no obvious hemolysis or vascular stimulation; the pharmaceutical composition has a better tumour inhibiting rate than solubilisation of surfactants.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 26, 2015
    Inventors: Kaiyong Tang, Junfang Pan, Qin Zhu, Tong Fang, Chengcheng Niu, Wanhai Li, Wei Lv, Chen Qing, Guorong Fan
  • Publication number: 20150056300
    Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kDa to about 90 kDa or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kDa to about 90 kDa.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 26, 2015
    Applicant: BIND Therapeutics, Inc.
    Inventors: David Dewitt, Maria Figueiredo, Hong Wang, Greg Troiano, Young-Ho Song
  • Publication number: 20150050210
    Abstract: The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives. The invention further relates to a process for preparing a pharmaceutical composition which comprises bendamustine and its derivatives prepared by hot melt extrusion using pharmaceutically acceptable excipients. The invention also relates to such pharmaceutical compositions and hot melt extrudates.
    Type: Application
    Filed: March 25, 2013
    Publication date: February 19, 2015
    Inventors: Akif Emre Tuereli, Bernd Baumstuemmler, Richard Ammer
  • Publication number: 20150045289
    Abstract: The present invention relates to the method of pre-preparing pharmaceutical compositions for therapeutic uses, particularly pre-preparing medications for treating patients (e.g., cancer patients and the like) by intravenous infusion.
    Type: Application
    Filed: July 14, 2014
    Publication date: February 12, 2015
    Inventors: MICHAEL L. WEST, Tracey J. BROWN
  • Publication number: 20150037437
    Abstract: A chemotherapy agent or a pharmaceutical composition including chemotherapy agent and artificial cerebrospinal fluid, wherein the chemotherapy agent at a concentration of between 0.01 mg/ml and 0.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 5, 2015
    Applicant: RENISHAW PLC
    Inventors: Steven Streatfield Gill, Edward White
  • Publication number: 20150037375
    Abstract: Provided herein are 3-dimensional drug-eluting materials comprising biodegradable polymer(s), one or more bioactive agents and entrapped air. Various embodiments of the methods and compositions described herein are based, in part, on the discovery of hydrophobic doping agents that can be used in the manufacture of polymeric drug delivery compositions that permit the encapsulation of air, thereby permitting tunable drug release via controlled air removal. Such compositions are particularly useful for delivering therapeutically effective doses of one or more bioactive agents to a subject over an extended period of time (e.g., days, weeks, or months).
    Type: Application
    Filed: July 19, 2012
    Publication date: February 5, 2015
    Applicant: TRUSTEES OF BOSTON UNIVERSITY ET AL
    Inventors: Mark W. Grinstaff, Jesse Wolinsky, Stefan Yohe, Jonah Andrew Kaplan, Eric John Falde, Joseph Steven Hersey
  • Publication number: 20150031628
    Abstract: Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.
    Type: Application
    Filed: August 6, 2014
    Publication date: January 29, 2015
    Inventor: Curtis A. Spilburg
  • Publication number: 20150031644
    Abstract: The invention provides novel amphiphilic drug-drug conjugates useful as cancer therapeutics, and compositions and methods thereof.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 29, 2015
    Inventors: Deyue Yan, Ping Huang, Xinyuan Zhu, Wei Huang, Yongfeng Zhou
  • Publication number: 20150030672
    Abstract: A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 29, 2015
    Inventors: Chunlei LI, Lan ZHANG, Caixia WANG, Li ZHANG, Dongmin SHEN, Yanhui LI, Xian XIU, Min LIANG, Yongfeng LI
  • Patent number: 8940333
    Abstract: An amphiphilic block copolymer is disclosed. The amphiphilic block copolymer includes one or more hydrophilic polymers, one or more hydrophobic polymer, and one or more zwitterions. The invention also provides a nanoparticle and carrier including the amphiphilic block copolymer for delivery of water insoluble drugs, growth factors, genes, or water insoluble cosmetic substances.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 27, 2015
    Assignee: Industrial Technology Research Institute
    Inventors: Ming-Fa Hsieh, Hsuen-Tseng Cha'ng, Chin-Fu Chen, Yuan-Chia Chang, Pei Kan, Tsai-Yu Lin
  • Patent number: 8940754
    Abstract: A 10?-fluoro-vinca alkaloid compound or its pharmaceutically acceptable salt is disclosed, as are methods of its preparation and use. A disclosed 10?-fluoro-vinca alkaloid compound has better cytotoxic potency against leukemia and cancer cell lines, and is about 8-times more cytotoxic to a multiple drug resistant cancer cell line than is a parental 10?-unsubstituted vinca alkaloid.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: January 27, 2015
    Assignee: The Scripps Research Institute
    Inventor: Dale L. Boger
  • Patent number: 8940286
    Abstract: A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: January 27, 2015
    Assignees: The University of Tokyo, Tokyo University of Pharmacy and Life Sciences
    Inventors: Hirotaka Matsuo, Nariyoshi Shinomiya, Takahiro Nakamura, Tappei Takada, Hiroshi Suzuki, Yuki Ikebuchi, Kousei Ito, Kimiyoshi Ichida
  • Publication number: 20150017243
    Abstract: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 15, 2015
    Inventor: JOSH REYNOLDS
  • Patent number: 8927564
    Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: January 6, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Donald G. Payan, Sylvia Braselmann
  • Publication number: 20150004219
    Abstract: Liposomes with an entrapped amphipathic weak base and alkyl or aryl sulfonate are described as well as methods of making and using these liposomes.
    Type: Application
    Filed: February 3, 2013
    Publication date: January 1, 2015
    Inventors: Yechezkel Barenholz, Tal Berman, Doron Friedman
  • Publication number: 20140378409
    Abstract: An antitumor effect potentiator of another antitumor agent, including an acylthiourea compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein R1 represents a C1-6 alkyl group which may have a substituent, while the substituent represents any one of a hydroxyl group, a C3-10 cycloalkyl group, a C1-6 alkoxy group which may have a substituent, a C1-6 alkylamino group which may have a substituent, a C1-6 alkanoylamino group, a C1-6 alkylsulfonyl group, a C6-14 aromatic hydrocarbon group which may have a substituent, a saturated or unsaturated heterocyclic group which may have a substituent, a C1-6 alkylaminocarbonyl group which may have a substituent, a saturated or unsaturated heterocyclic carbonyl group which may have a substituent; R2 represents a fluorine atom or a chlorine atom; and R3 represents a hydrogen atom, a fluorine atom, or a chlorine atom.
    Type: Application
    Filed: December 27, 2012
    Publication date: December 25, 2014
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hidenori Fujita, Masanori Kato
  • Publication number: 20140378403
    Abstract: This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 25, 2014
    Inventors: Zhenfeng Duan, Francis J. Hornicek
  • Publication number: 20140378944
    Abstract: Methods and devices for delivering an agent to a solid tissue in vivo for assessment of efficacy are described. One method involves withdrawing of a needle from and injecting of the agent into the solid tissue; another method involves delivering the agent using a plurality of microdialysis probes to a solid tissue.
    Type: Application
    Filed: July 10, 2014
    Publication date: December 25, 2014
    Inventors: Jason Frazier, Richard Klinghoffer, Marc Grenley
  • Patent number: 8916537
    Abstract: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: December 23, 2014
    Assignee: Aposense Ltd.
    Inventors: Ilan Ziv, Hagit Grimberg
  • Publication number: 20140370121
    Abstract: Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 18, 2014
    Inventors: John J. Turchi, Sarah Shuck
  • Publication number: 20140371258
    Abstract: Provided herein are water-soluble polymer conjugates of topotecan, along with compositions comprising the conjugates and related methods of making and using the same.
    Type: Application
    Filed: December 16, 2011
    Publication date: December 18, 2014
    Applicant: Nektar Therapeutics
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier, Michael D. Bentley, Tacey X. Viegas
  • Patent number: 8912212
    Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: December 16, 2014
    Assignee: BIND Therapeutics, Inc.
    Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
  • Publication number: 20140363491
    Abstract: The present disclosure provides lipid-containing compositions, including targeted liposomes encapsulating drug, and pharmaceutical formulations thereof, as well as methods for the making and using the lipid-containing compositions, including the use of the targeted liposomes in the treatment of cancer and other diseases.
    Type: Application
    Filed: May 9, 2014
    Publication date: December 11, 2014
    Applicant: Mebiopharm Co., Ltd.
    Inventors: Kazushi OKADA, Tadayuki IBUKI, Donghyun KIM, Tadashi FUJISAWA
  • Publication number: 20140363522
    Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.
    Type: Application
    Filed: May 13, 2014
    Publication date: December 11, 2014
    Inventors: Ernst LENGYEL, Kristin NIEMAN, Hilary KENNY
  • Publication number: 20140357659
    Abstract: Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Ute Hoch, Christine Taylor Brew, Stephen David Harrison, Dennis G. Fry, Darin W. Davis
  • Publication number: 20140348854
    Abstract: The invention provides compositions and methods for utilizing human epididymal secretory protein E4 (HE4) in the prevention and treatment of cancer and other human diseases.
    Type: Application
    Filed: June 6, 2012
    Publication date: November 27, 2014
    Applicant: WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND
    Inventors: Richard G. Moore, Rakesh K. Singh
  • Publication number: 20140348958
    Abstract: A compound of formula (I), a positional or structural isomer thereof, or a pharmaceutically acceptable base addition salt or acid addition salt thereof, use thereof as a medicament, in particular an anticancer medicament.
    Type: Application
    Filed: September 12, 2012
    Publication date: November 27, 2014
    Inventors: Pierre Chalard, Florence Caldefie-Chezet, Laetitia Delort, Kirti Patel
  • Publication number: 20140341849
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Deng PAN, Masha Kocherginsky, Suzanne D. Conzen
  • Publication number: 20140343088
    Abstract: Disclosed is a trolox derivative-modified fat-soluble anti-cancer pharmaceutical compound having a structure as represented by formula I or II. An active moiety of the anti-cancer pharmaceutical compound, camptothecin or a camptothecin derivative, is covalently bonded to a lipophilic moiety, a trolox ester or a trolox amide, by a linking group to form the fat-soluble anti-cancer pharmaceutical compound. Also disclosed are a preparation, preparing method and use of the pharmaceutical compound.
    Type: Application
    Filed: October 18, 2012
    Publication date: November 20, 2014
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventor: Yuehua Zhang
  • Publication number: 20140335191
    Abstract: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Inventor: JOSH REYNOLDS
  • Patent number: 8883775
    Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: November 11, 2014
    Assignee: Cascade Prodrug Inc.
    Inventors: John G. Curd, John F. W. Keana, Alshad S. Lalani, Paul B. Westberg, Bradford Goodwin, W. David Henner
  • Patent number: 8877715
    Abstract: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: November 4, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira